Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 5Neoplasms 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Sarcoma 1Peritoneal Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Lymphedema 1Locally Advanced Rectal Cancer 1HER2 Positive Esophagogastric Cancer 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Cachexia 1Advanced Esophageal Cancer 1

Interventions

Cyclophosphamide 53Etoposide 33Temozolomide 28Irinotecan 28Melphalan 25Filgrastim 25Topotecan 24Carboplatin 243-Iodobenzylguanidine 23Isotretinoin 20Granulocyte Colony-Stimulating Factor 17sargramostim 16humanized 3F8 anti-GD2 monoclonal antibody 16dinutuximab 16Granulocyte-Macrophage Colony-Stimulating Factor 16fludarabine 15Vincristine 15Doxorubicin 15Cisplatin 15Peripheral Blood Stem Cell Transplantation 14Interleukin-2 14Busulfan 13naxitamab 12Thiotepa 12Radiotherapy 12aldesleukin 11fludarabine phosphate 10etoposide phosphate 8Mesna 8Ifosfamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroblastoma × Combined Modality Therapy × Clear all
NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡